Lintuzumab Ac-225

Drug Profile

Lintuzumab Ac-225

Alternative Names: 225Ac-HuM-195; 225Ac-lintuzumab; AC225 MOAB M195; Ac225 monoclonal antibody M195; Actimab-A; Actimab-M; Actinium-225 (225Ac)-Lintuzumab; Actinium-225-labelled HuM195; HuM195-Ac-225; Lintuzumab-Ac225; SMART actinium-225-M-195

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator PDL BioPharma
  • Developer Actinium Pharmaceuticals; Baylor Research Institute; Memorial Sloan-Kettering Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD33 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I Multiple myeloma

Most Recent Events

  • 15 Jun 2017 Lintuzumab Ac-225 is available for licensing as at 15 June 2017
  • 24 May 2017 Lintuzumab Ac-225 receives Orphan Drug status for Acute myeloid leukaemia (First-line therapy, In the elderly) in European Union
  • 28 Feb 2017 Actinium Pharmaceuticals receives notice of allowance from United States Patent and Trademark Office for lintuzumab Ac-225
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top